News Healthcare Deals, Investments & Update Week ending Dec 22nd 2025
- Medline (NASD: MDLN) soars 41% in Nasdaq debut after IPO backed by Blackstone, Carlyle, and Hellman & Friedman, raising $6.26 billion in 2025’s largest offering Medline’s IPO drew strong investor interest, valuing the firm at $46 billion after a 41% stock surge. Generating $977 million in profit on $20.6 billion in revenue, the company’s global manufacturing network limits tariff risks. Its steady, cash-rich model contrasts with typical volatile, high-growth market entrants. (Link)
- Cencora (NYSE: COR) (formerly AmerisourceBergen) to acquire majority stake in OneOncology in $5 billion deal, after already holding a minority position, bolstering community oncology network and specialty distribution strategy The deal combines debt financing and an equity rollover to maintain physician autonomy while integrating OneOncology’s nationwide network within Cencora’s platform. The partnership enhances clinical trials, care coordination, and technology access, supporting community-based cancer care. Analysts see the transaction as a strong vote of confidence in oncology’s growth potential. (Link)
- BioMarin (NASD: BMRN) to acquire Amicus Therapeutics (NASD: FOLD) for $4.8 billion, expanding rare disease portfolio with Galafold and Pombiliti-Opfolda The acquisition strengthens BioMarin’s rare disease pipeline by adding Amicus’ Galafold and Pombiliti-Opfolda therapies and kidney candidate DMX-200. These assets complement BioMarin’s enzyme replacement treatments and Voxzogo, supporting revenue growth and global expansion. Analysts view the deal as a strategic fit, reflected in BioMarin’s post-announcement stock surge. (Link)
- Matt Holt to lead creation of Thoreau, a $30 billion AI‑enabled health‑tech venture combining New Mountain Capital’s Datavant, Swoop, Machinify, Smarter Technologies and Office Ally The deal would combine five healthcare tech companies into one AI-focused platform aimed at cutting medical costs for payers and providers. New Mountain Capital is weighing a structure that returns about 12 billion dollars in cash plus equity and warrants to its investors, exceeding prior portfolio valuations. (Link)
- HCAP Partners invests in Puzzle Healthcare to scale post‑acute care coordination platform across U.S. skilled nursing facilities The investment will accelerate Puzzle Healthcare’s expansion of post-acute care coordination services that track patients for 90 days after skilled nursing stays. Operating in 230 facilities across 15 states, Puzzle uses data-driven workflows to reduce readmissions, lower costs, and safeguard providers from Medicare penalties through improved care continuity. (Link)
- Medtronic plc (NYSE: MDT) and MiniMed move toward Nasdaq listing with S‑1 filing for diabetes business IPO The S‑1 filing initiates Medtronic’s plan to spin off its Diabetes unit as MiniMed, which intends to trade on Nasdaq under “MMED.” The IPO and potential split‑off structure depend on regulatory approval and market conditions. MiniMed will focus on AI‑enabled insulin delivery and continuous glucose monitoring technologies. (Link)
- Philips to acquire SpectraWAVE to advance AI‑enabled intravascular coronary imaging and physiology through HyperVue and X1‑FFR The acquisition integrates SpectraWAVE’s X1‑FFR software, which measures coronary blood flow from angiograms, with its HyperVue imaging platform combining OCT and NIRS to visualize arterial plaque. Philips aims to unify AI-driven imaging and physiology tools to improve stent placement accuracy and standardize coronary disease treatment quality worldwide. (Link)
- HealthStream (NASD: HSTM) acquires MissionCare Collective in deal valued up to $40 million to build largest U.S. caregiver career network The deal brings MissionCare Collective’s 5.2‑million caregiver network and platforms like myCNAjobs and CoachUp Care into HealthStream’s hStream ecosystem. It expands workforce solutions to home health and long‑term care providers, addressing caregiver shortages and aging‑population demands through enhanced recruiting, training, and retention tools supported by cash, stock, and earnout terms. (Link)
- XOMA Royalty (NASDAQ: XOMA) to acquire Generation Bio (NASDAQ: GBIO) gaining exposure to Moderna collaboration and ctLNP nucleic acid delivery platform The transaction gives Generation Bio shareholders cash and contingent value rights linked to cash reserves, lease savings, and potential revenues from the Moderna partnership and ctLNP platform. Executed through a tender offer and merger, the deal has 15% shareholder support and is expected to close by February 2026. (Link)
- Accordion acquires Pinnacle Healthcare Advisors, via its financial sponsors Charlesbank Capital Partners and Motive Partners, to build scaled revenue cycle management platform for health systems and healthcare investors The acquisition merges Pinnacle’s expertise in cash acceleration, AR reduction, and EHR optimization with Accordion’s AI-driven RCM Center of Excellence. The combined platform aims to help health systems tackle margin pressures, payer complexity, and denial rates by improving revenue performance through advanced analytics and integrated operational support. (Link)
- INVO Fertility (NASD: IVF) to acquire Indiana clinic Family Beginnings to expand Midwest fertility footprint after $4.0M private placement The acquisition supports INVO Fertility’s U.S. expansion strategy centered on assisted reproductive technology, including INVOcell-based intravaginal culture. Family Beginnings adds a reputable Indiana clinic with $1.2 million in annual revenue and a full fertility service lineup. The $750,000 deal combines cash and preferred stock, with founder Dr. James Donahue remaining as leader. (Link)
- Enjoin acquires Paediatric Resource Group to expand paediatric and adult CDI, APR‑DRG and physician advisor solutions for U.S. hospitals The acquisition combines Enjoin’s adult DRG assurance capabilities with PRG’s paediatric and neonatal CDI expertise to create a unified, tech-enabled revenue integrity platform. It enhances support for children’s and acute-care hospitals through utilization review and denials management, expanding nationwide CDI services under 3 Boomerang’s strategic healthcare platform. (Link)
- Sentact acquires Performance Health Partners and Vizient Patient Safety Organization to build an integrated, analytics‑driven patient safety and incident reporting platform across U.S. care settings The acquisitions expand Sentact’s patient safety capabilities by integrating Performance Health Partners’ advanced incident management system and the Vizient Patient Safety Organization’s nationwide collaborative. Combined, they enhance data-driven risk analysis, workflow automation, and advisory support to help healthcare providers identify risks, improve safety practices, and elevate clinical outcomes systemwide. (Link)
- Prosperous Health acquires Peninsula Health Center to expand integrated outpatient mental health and addiction services across Palos Verdes and the South Bay The merger creates a comprehensive behavioral health network offering detox, outpatient, and long-term therapy within integrated care plans for addiction and mental illness. Combining Prosperous Health’s physician-led model with Peninsula’s accredited programs enhances local access, continuity of care, telehealth services, and collaboration with hospitals and public health partners. (Link)
News Healthcare Deals, Investments & Update Week ending Dec 15th 2025
- Novo Nordisk completes $4.7B acquisition of Akero Therapeutics (Nasdaq: AKRO) with additional $0.5B CVR tied to EFX approval Akero Therapeutics becomes a wholly owned subsidiary following the acquisition, delisting its shares from Nasdaq. The agreement includes additional payment contingent on FDA approval of EFX for MASH-related cirrhosis. The move strengthens Novo Nordisk’s liver and metabolic disease portfolio and expands its U.S. research and development operations. (Link)
- Teleflex (NYSE: TFX) divests OEM, urology, and acute care units in $2B deals with Montagu, Kohlberg, and Intersurgical Teleflex is restructuring to prioritize its cardiovascular portfolio through divestments totalling $2 billion. Montagu and Kohlberg will acquire its OEM division, while Intersurgical will buy acute care and urology lines. Proceeds will partly fund a $1 billion share repurchase, with both deals expected to close in late 2026. (Link)
- Lumexa Imaging (NASD: LMRI) raises nearly $463M in IPO, earns Moody’s credit upgrade after debt reduction plan The IPO valued Lumexa Imaging at $1.76 billion, with proceeds mainly used to refinance debt and extend maturities, reducing obligations by over $370 million. Moody’s upgraded its rating due to improved credit strength. Founded in 2018, the company operates 184 imaging centers and continues expanding through acquisitions and AI initiatives. (Link)
- Cycle Pharmaceuticals to acquire Applied Therapeutics (Nasdaq: APLT) to advance CNS rare disease treatments through lead drug candidate Govorestat Applied Therapeutics shareholders will receive cash and contingent value rights tied to regulatory and sales milestones under the merger agreement. Cycle will provide up to $8.5 million in bridge funding to support operations until closing. The board unanimously approved the deal, expected to complete in early 2026. (Link)
- HarmonEyes completes acquisition of iFocus Health to expand AI-driven solutions for ADHD treatment The merger integrates iFocus Health’s AI technology into HarmonEyes’ behavioral health platform to advance personalized ADHD care. Combining data analytics and machine learning, the partnership aims to improve diagnosis, treatment, and patient outcomes while expanding evidence-based, AI-driven mental health solutions for broader accessibility and clinical scalability. (Link)
- Handspring Health acquires Joon Care to expand paediatric and adolescent behavioral health services The merger combines Handspring Health’s paediatric care focus with Joon Care’s virtual therapy model to enhance youth mental health services. It expands market reach through Joon’s Washington base and payer ties while integrating technology for improved engagement and outcomes, supporting Handspring’s growth and evidence-based, scalable care model. (Link)
- Perimeter Solutions to acquire Medical Manufacturing Technologies in $685 million cash deal The transaction adds Medical Manufacturing Technologies’ expertise in minimally invasive device production to Perimeter Solutions’ portfolio, aligning with its strategy to invest in high-margin growth sectors. Funded by debt and cash, the deal expands Perimeter’s presence into medical manufacturing and is expected to close in early 2026 pending approval. (Link)
- AMSURG acquires Advanced Center for Surgery to expand into Central Pennsylvania outpatient market The deal adds a 12,500-square-foot surgical center in Altoona with four operating rooms and 17 specialists to AMSURG’s network. Known for outpatient joint replacements, the facility strengthens AMSURG’s Pennsylvania presence and supports its mission to empower independent physicians and expand access to quality, value-based outpatient surgical care. (Link)
- Select Medical acquires Landmark Hospital of Savannah from Landmark Holdings of Florida to expand long-term acute care services The acquisition adds a 50-bed long-term acute care hospital in Savannah to Select Medical’s network, replacing its former local facility. The site now treats medically complex patients needing extended recovery. This expansion strengthens Select Medical’s Southeast presence and supports its nationwide growth in post-acute and rehabilitation services. (Link)
- Mercy Health and Lifepoint Health open new 72-bed Behavioral Hospital in Youngstown to expand mental health and substance abuse care The new 72-bed behavioral hospital provides inpatient care for mental health and substance use disorders, including programs for veterans and first responders. Using evidence-based, trauma-informed methods, it aims to ease ER burdens and improve community support, with inpatient admissions starting in January and outpatient services launching in May. (Link)
News Healthcare Deals, Investments & Update Week ending Dec 8th 2025
- Hims & Hers Health (NYSE: HIMS) to acquire YourBio Health to add patented, pain-free TAP and HALO blood sampling technology to its wellness platform The acquisition will integrate virtually painless microneedle blood collection into a broader direct‑to‑consumer health platform, enabling fast, high‑quality capillary sampling outside traditional clinics. Protected microtechnology around device design, sample handling, and integration supports future test expansion, while incoming scientific and executive leaders will steer development of more user‑friendly diagnostics after the all‑cash deal closes. (Link)
- Overjet acquires Toledo AI startup DentalBee to combine voice-driven documentation with dental imaging in a unified clinical intelligence platform The transaction pairs real-time voice capture of periodontal measurements, notes, and referral details with AI analysis of X‑rays to create fully structured dental records while easing documentation burden for clinicians. It also underscores Northwest Ohio’s emergence as an AI hub, with regional economic development groups credited for helping the startup reach acquisition. (Link)
- Joi + Blokes acquires HerMD to build a nationwide virtual women’s health platform for menopause, sexual health, and hormonal care The merger will expand access to longer virtual consults with hormone and menopause specialists, broader treatment options, and preventive lab support in every state, while adding research participation opportunities. HerMD’s education-first approach will drive new national learning initiatives as the combined platform works to deliver more consistent, empathetic, evidence-based care to underserved midlife women. (Link)
- Lightbeam Health Solutions acquires Syntax Health to integrate value-based contracting and actuarial modelling into its AI-enabled population health platform The acquisition adds a contract‑modelling engine and actuarial talent into a broader value‑based care operating system, allowing payers and providers to rapidly simulate deals, align on assumptions, and project financial results with more confidence. By tying benchmarking and forecasting directly to contract design, the combined platform aims to reduce administrative complexity and refocus attention on population outcomes. (Link)
- Avandra Health acquires DatCard Systems and Sorna Corporation to build a unified global medical imaging and clinical data platform for patient care and research The enlarged platform will connect distribution tools already embedded at thousands of sites with a federated, de‑identified imaging network, making it easier for hospitals to share studies and for life sciences partners to tap high‑value data. By investing in upgrades and support while preserving existing brands, the organization aims to unlock siloed imaging for both care and research. (Link)
- Ciba Health partners with Quikcard to launch personalized, prevention‑first metabolic and chronic care programs for Canadians The partnership brings structured 12‑month programs with dietitian and health‑coach support, personalized plans, and continuous tracking to help members address metabolic risk and chronic conditions through lifestyle change rather than medication alone. Validated outcomes include meaningful HbA1c drops, sharply reduced overall drug use and costs, and GLP‑1 Step Down participants lowering GLP‑1 dependence while losing weight over six months. (Link)
- XRHealth acquires Innerworld to build an immersive, stepped-care XR platform for mental health and rehabilitation The combined platform will pair always‑on, community‑based mental health support—via live events, facilitator‑led groups, and global peer interaction—with existing VR/AR treatments for pain, rehab, PTSD, stress, addiction, and OCD. By adding Innerworld’s founder as chief clinical officer and building on prior XR acquisitions, the company is constructing a stepped‑care, AI‑enhanced XR ecosystem spanning self‑help to clinician‑guided therapy. (Link)
- Cerbo acquires OptiMantra, via its financial sponsors Search Fund Partners, Applied Equity Partners, Manifestations Capital, Hunter Search Capital, Endurance Search Partners, and Red Forest Capital to build AI-powered practice platform for specialty and integrative care The merger creates a single EMR and practice‑management platform for integrative, functional, direct primary care, concierge, behavioral health, and IV/injectable practices, targeting the operational needs of membership‑ and cash‑pay models. Backed by multiple financial sponsors, the combined team will co‑develop AI‑enabled workflows, CRM-driven growth tools, and upgraded payment capabilities while keeping founders engaged and a customer‑first culture intact. (Link)
- BriteLife Recovery acquires Summit Behavioral Health to add intensive outpatient services to its East Coast addiction treatment network The deal extends care into flexible day and evening intensive outpatient programming at the Princeton Junction site, supported by transportation, alumni services, family recovery programming, and enhanced staff training. BriteLife’s broader network across several East Coast states, plus insurance acceptance and scholarships, is intended to make trauma‑informed, relationship‑centered treatment more accessible. (Link)
- CQ Medical acquires Bionix Radiation Therapy business unit to expand global radiotherapy positioning and marking portfolio The acquisition brings additional radiotherapy accessories and a seasoned sales team under the same umbrella, broadening an existing suite of positioning, immobilization, and image‑guided treatment devices used in oncology. CQ Medical plans to absorb the new product lines into its current manufacturing footprint while Bionix redirects attention and investment to its remaining ambulatory care portfolio. (Link)
- Natera (NASD: NTRA) acquires Foresight Diagnostics in up to $450 million deal to expand minimal residual disease cancer testing portfolio The transaction adds ultra‑sensitive PhasED‑Seq assays that can detect lymphoma relapse at very low circulating tumour DNA levels long before standard imaging, alongside a CLIA‑registered lab and lymphoma expertise that deepen the existing MRD offering. It follows settlement of past IP disputes and comes amid strong cancer testing growth but continued net losses. (Link)
- Paradigm Health raises $78 million Series B from ARCH Venture Partners, DFJ Growth, F-Prime, General Catalyst, GV, Lux Capital, Mubadala Capital, and American Cancer Society’s BrightEdge Fund to expand AI-enabled clinical trial infrastructure The platform links biopharma sponsors with 166 provider organizations and 2,100 care sites across 45 states. Automated matching and site-feasibility tools let health systems enrol up to four times faster and reduce clinician burden, while a new design service embeds interventional and pragmatic trials directly into routine workflows and expands into neuroscience, cardiovascular, and metabolic research. (Link)
- Artera raises $65 million from Lead Edge Capital, Jackson Square Ventures, Health Velocity Capital, Heritage Medical Systems, and Summation Health Ventures to scale agentic AI for patient communication The company is using a decade of real‑world communication data to train AI that automates routine scheduling, intake, billing, and messaging across more than 1,000 provider organizations and 2 billion yearly interactions. Its “flow agents” already handle most exchanges without staff, while co‑pilot tools summarize, translate, and surface priority outreach, saving substantial administrative time. (Link)
- Curi Bio raises $10 million Series B led by DreamCIS to scale human iPSC-based preclinical platforms and advanced functional data analysis for drug discovery Curi Bio is expanding a platform that uses high‑purity human iPSC‑derived cells, tissue‑specific 3D biosystems, and rich functional data to predict human drug responses more accurately than animal or 2D models. These assays guide candidate selection and IND decisions across multiple diseases, while partner DreamCIS contributes clinical research and regulatory expertise to boost trial success. (Link)
- Lyric Bio, Inc. raises $6.6 million seed round led by The Venture Collective, with Black Diamond Ventures, Draper Associates, Lucas Venture Group, Meiji Seika Pharma, SOSV, and others to advance donor‑derived therapeutics biomanufacturing Lyric Bio is building ultra‑high‑density 3D bioreactors that mimic human tissue to manufacture donor‑derived therapies at scale, starting with IVIg and SCIg in a $20 billion market. By targeting up to 100x efficiency gains, the team aims to slash costs, cut reliance on human donors, and deliver more consistent, accessible immunoglobulin products. (Link)
News Healthcare Deals, Investments & Update Week ending Dec 1st 2025
- Patient Square Capital completes $2.6 billion take-private acquisition of Premier, Inc (NASD: PINC), paying $28.25 per share in all-cash deal. The deal takes Premier private and keeps its operations focused on powering healthcare improvement through analytics, supply chain offerings, collaboratives, and advisory services. As part of a larger healthcare-focused portfolio, the company is expected to use additional capital and expertise to enhance technology-driven tools that help providers improve outcomes and reduce costs. (Link)
- Bruker Corporation (NASD: BRKR) acquires AST Revolution to advance WAVE and Arc rapid antimicrobial susceptibility testing technologies and expand clinical diagnostics portfolio The deal shifts a revitalized rapid testing platform into a larger diagnostics ecosystem, keeping focus on delivering quicker, clinically actionable antimicrobial susceptibility results. With prior investment having stabilized and advanced the WAVE and Arc systems, the new owner is expected to use its scale, market access, and technical depth to speed adoption in laboratories and hospitals. (Link)
- MDI NetworX acquires Cobalt MedPlans (Clarity Performance Solutions) from Cobalt Health Solutions, a Blue Cross and Blue Shield of Kansas City Subsidiary, to Expand U.S. Payer Services and Deploy InsightPro AI Platform The deal adds 250 U.S. staff and two Kansas delivery centers, lifting the company’s global workforce above 7,500 and growing its domestic operations to four sites. It plans to intensify investment in automation, analytics, and workforce capabilities to deliver scalable, end-to-end payer operations while tightening control of administrative costs. (Link)
- US Fertility partners with L Catterton and Amulet Capital Partners in new co-lead investor structure to expand access to advanced reproductive care across the U.S. The updated ownership structure preserves significant physician ownership while adding growth capital and consumer-health expertise to scale US Fertility’s clinics, labs, and research programs. It supports broader access to IVF, IUI, genetic testing, and related services, while reinforcing a physician-led, patient-centered care model for tens of thousands of new patients annually. (Link)
- MedEdge Holdings launches with $450 million management-led buyout to integrate Abyrx’s biomaterials portfolio and Kairuku’s surgical SaaS platform The holding company will merge biomaterials and surgical software capabilities to streamline product sourcing, inventory control, and case coordination for hospitals and OR teams. Profitable operations plus new capital will fund acquisitions of 10–15 commercial-stage products, aiming to cut administrative complexity while broadening access to next‑generation surgical technologies. (Link)
- FluidAI Medical acquires Emmetros Limited, developer of SparxConnect, to strengthen AI-driven Stream Inara patient engagement The integration focuses on stronger postoperative monitoring and communication, using collaboration tools to guide patients before procedures and through home recovery. It supports earlier discharge while preserving visibility into outcomes and patient‑reported data, and complements existing monitoring, surgical decision support, and recovery programs to boost throughput, bed utilization, and personalized recovery planning. (Link)
- Innova Therapeutics acquires Enci Therapeutics to advance IVT-8086, a first-in-class monoclonal antibody targeting SFRP2 in solid and hematologic cancers The deal centralizes control of IVT-8086 to accelerate its development as a targeted therapy against a key signalling pathway driving angiogenesis, tumour growth, immune evasion, and metastasis. Strong preclinical data support its potential both as monotherapy and in combination with checkpoint inhibitors, alongside a companion diagnostic to guide detection, prognosis, and relapse monitoring. (Link)
- MiCare Path acquires Compwell, LLC to accelerate national expansion of AI-powered virtual care platform The platform now supports large, multispecialty patient panels with reimbursable programs for remote monitoring and ongoing care management. New capital and the Compwell integration will grow clinical services, deepen health system collaborations, and accelerate AI-driven workflow automation, enabling more proactive, personalized virtual care that extends clinician support into patients’ daily lives. (Link)
- Brown’s Medical Imaging and Prestige Medical Imaging merge to expand nationwide, multi-vendor medical imaging service capabilities The merged business broadens nationwide coverage while maintaining a vendor-agnostic service model with strong uptime and response commitments. A 150‑plus engineer field force provides fast remote and onsite support, underpinned by a customer‑first, end‑to‑end service philosophy. Leadership promotions reinforce continuity and position the company for its next phase of growth. (Link)
- AleraCare, backed by Hildred Capital Management, to merge with Pure Healthcare to Form National Platform for Ambulatory Infusion and Specialty Care The merged platform operates 77 infusion centers in 14 states, pairing complex-chronic-care expertise with expanding home and alternate-site services. A unified contracting and technology backbone supports payors, providers, and biopharma with faster therapy starts, better adherence, and AI-enabled scheduling, benefits checks, and real-time outcomes tracking, while maintaining a safety- and compassion-focused culture. (Link)
News Healthcare Deals, Investments & Update Week ending Nov 24th 2025
- Abbott (NYSE: ABT) to acquire Exact Sciences (NASD: EXAS) in $21 Billion All-Cash Deal to Expand Global Cancer Screening and Precision Oncology Diagnostics Portfolio The deal will make Exact Sciences a subsidiary, helping Abbott reach $12 billion in diagnostics sales. Exact’s Madison, Wisconsin presence and leadership will remain, with the CEO advising during transition. Shareholder and regulatory approvals are expected before closing in mid-2026. (Link)
- Merck (NYSE: MRK) to acquire Cidara Therapeutics (NASD: CDTX) for $9.2 Billion, Gaining Late-Phase Antiviral CD388 for Influenza Prevention After the deal’s approval, Cidara Therapeutics will strengthen Merck’s presence in antivirals with CD388 targeting high-risk influenza populations. The acquisition structure ensures all Cidara shares are purchased, pending regulatory clearance, with closing planned for the first quarter of 2026. (Link)
- GE Healthcare (NASD: GEHC) to acquire Intelerad in $2.3 Billion Deal to Expand Cloud-Enabled and AI-Driven Imaging Platform for Radiology, Cardiology, and Outpatient Enterprise Markets The integration will modernize imaging workflows for outpatient and ambulatory care, leveraging Intelerad’s SaaS and AI strengths to streamline operations, unify data, and improve provider efficiency. Backed by global reach and financial flexibility, GE HealthCare expects significant recurring revenue and top-line growth from expanded cloud imaging offerings. (Link)
- Solventum (NYSE: SOLV) to acquire Acera Surgical for $725 Million Plus Milestone Payments, Expanding Advanced Wound Care Portfolio with Synthetic Tissue Matrices Technology Acera’s Restrata product, a fully resorbable electrospun fiber matrix, treats hard-to-heal acute care wounds by supporting cellular growth and healing. Solventum will use its sales expertise and international presence to accelerate Restrata’s adoption, aiming for commercial and operational synergies that drive leadership in advanced regenerative wound care. (Link)
- Halozyme Therapeutics (NASD: HALO) completes $750 Million Acquisition of Elektrofi, Unlocks Hypercon™ Technology for High-Concentration Biologics and Expands Drug Delivery Offerings Hypercon™ enables highly concentrated biologics to be delivered subcutaneously, improving patient convenience and supporting at-home care. Halozyme Therapeutics will pursue royalty-based licensing for products built on Elektrofi’s technology, with expected milestone payments and clinical launches that could begin driving revenues and broader market impact starting in 2030. (Link)
- Nanox Imaging (NASD: NNOX) to acquire VasoHealthcare IT from Vaso Corporation (OTCQX: VASO) for Up to $800,000 to Accelerate U.S. Rollout of FDA-Cleared AI Medical Imaging Solutions Nanox’s platform brings real-time AI analysis and automated detection to routine CT imaging, offering multiple FDA-cleared solutions for radiology and cardiology. The acquisition leverages VasoHealthcare IT’s healthcare relationships for broader market coverage, enabling faster hospital adoption and improved integration of AI-driven workflows for earlier chronic disease identification. (Link)
- RadNet (NASD: RDNT) acquires River Radiology, Strengthening New York Imaging Network and Expanding Lenox Hill Radiology’s Geographic Reach River Radiology’s Kingston facility delivers patient-centered care with advanced imaging services such as MRI, CT, PET/CT, 3D mammography, and ultrasound. Extended weekday hours and flexible scheduling support provider referrals. Its reputation for accurate reports, innovative screening, and compassionate service has defined medical imaging excellence across the Hudson Valley region. (Link)
- ClearPoint Neuro (NASD: CLPT) completes acquisition of IRRAS, Bringing IRRAflow System and Expanding Neurocritical Care and Drug Delivery Capabilities IRRAflow uses active irrigation and drainage to effectively treat brain haemorrhages, leading to faster clearance of blood, fewer catheter infections, and reduced risk of blockages compared to passive drains. Clinical studies report improved patient outcomes, shorter treatment duration, and lower hospital costs for those treated with this innovative technology. (Link)
- Reliant Healthcare and Care Fusion Rx Merge to Transform U.S. Infusion Therapy with Expanded Home and Ambulatory Service Platform Reliant Healthcare operates 14 infusion centers and specialty pharmacies across the southern U.S., while Care Fusion Rx brings expertise in advanced therapies—including immunoglobulin treatments—for chronic and rare diseases. The merger will drive national expansion with new locations, broader coverage, and investment in patient-focused care guided by experienced leadership. (Link)
- ARC Health Partners acquires Clarity Counselling Center, Adding Wilmington-Based Practice to 23-Group National Network and Expanding North Carolina Reach with Backing from Thurston Group Clarity Counselling Center offers therapy for individuals, couples, and families, specializing in anxiety, depression, trauma, ADHD, grief, and relationship issues in Wilmington, NC. Their team of over 13 therapists uses evidence-based therapies like CBT and DBT, ensuring client-therapist matching and personalized care for children, teens, and adults. (Link)
- MRO acquires Clinetic, via its financial sponsors Healthworx and Parthenon Capital Partners to Transform Patient Recruitment and Streamline Clinical Trial Enrollment with Scalable AI-EHR Integration Clinetic’s software uses AI to analyse both structured and unstructured patient data for real-time matching to clinical studies, dramatically accelerating recruitment. By integrating with EHRs, it supports secure workflow automation, precise cohort building, and reduces site workload—expediting enrollment for a nationwide hospital network and the Q-Centrix Research Network. (Link)
- OhioHealth, a Columbus-based nonprofit health system, is acquiring the independent 220-bed Fairfield Medical Center in Lancaster, OH. The deal will expand OhioHealth’s network to 17 hospitals and enhance regional care. The boards endorsed the merger in September 2024 after a non-binding letter of intent, with benefits including increased efficiencies, improved quality measures, and access to larger system resources for a growing population. Pending regulatory approvals and government filings, the deal is expected to close in 2026; no financial terms were disclosed. (Link)
- WVU Health System to acquire Independence Health System, Growing to 30-Hospital Network with $800 Million Investment Commitment Morgantown-based WVU Health System will acquire Greensburg’s Independence Health System, including five hospitals, physician groups, and subsidiaries, rebranding under WVU Medicine. WVU pledges $800 million over five years for facility modernization. Closing anticipated in fall 2026. (Link)
- Function Health raises $298 Million Series B led by Redpoint Ventures and a16z at $2.5 Billion valuation for Medical Intelligence Lab launch. Function Health offers comprehensive lab testing, body scans, and health data consolidation to detect over 1,000 conditions early via more than 100 biomarkers. The funding will expand U.S. locations, develop AI health features, and lower annual membership pricing. It also backs the Medical Intelligence Lab to advance health and longevity research for proactive care. (Link)
News Healthcare Deals, Investments & Update Week ending Nov 17th 2025
- Pfizer (NYSE: PFE) completes $7 Billion acquisition of Metsera (NASD: MTSR), adds MET-097i, MET-233i, and Expands Clinical Obesity Pipeline in Strategic Move for Cardiometabolic Therapeutics Leadership: The acquisition of Metsera brings new advanced obesity and cardiometabolic drug candidates, including injectable and oral therapies, accelerating innovation in this high-growth field. The deal enables rapid research, expanded expertise, and improved access to cutting-edge treatments, driven by milestone-based investments and integration of Metsera’s scientific strengths. (Link)
- Day One Biopharmaceuticals (NASD: DAWN) to acquire Mersana Therapeutics (NASD: MRSN) in $285 Million Deal to Advance Novel ADC Emiltatug Ledadotin for Adenoid Cystic Carcinoma and expanded Oncology Portfolio: Emiltatug ledadotin (Emi-Le) targets B7-H4 in adenoid cystic carcinoma, showing promising early anti-tumour activity for patients lacking effective therapies. Day One’s acquisition plan supports rapid clinical progress, with milestones tied to regulatory and commercial outcomes, aiming to advance this innovative cancer treatment for diverse, underserved populations. (Link)
- Galecto (NASD: GLTO) acquires Damora Therapeutics, With $285M Investment Led by Fairmount, Viking Global, Venrock, Wellington, RA Capital, Andreessen Horowitz, and Others to Advance Anti-mutCALR Therapies for Blood Cancers: The merger advances pioneering treatments for rare blood cancers, with lead antibody DMR-001 designed for greater potency and patient convenience. Expanded research and strategic guidance support rapid clinical progress, including novel therapies for acute myeloid leukaemia, improved trial designs, and broader access for affected patients. (Link)
- Fabric acquires UCM Digital Health, adding 400 Payer and Employer Clients, to expand AI-Powered Virtual Care Nationwide: The acquisition expands Fabric’s reach, offering AI-powered virtual care for over one million new lives and enhancing efficiency for patients, payers, and providers. By integrating UCM’s clinical expertise, Fabric improves seamless care delivery, cost savings, and access, strengthening its network across health systems and employer partnerships nationwide. (Link)
- Luma Health acquires Tonic Health from R1, Expanding Patient Intake and Follow-Up Solutions for Over 1,000 Health Systems and 100 Million Patients, for EHR-Integrated Care Innovation: The integration empowers healthcare organizations with advanced digital tools for automating patient intake, consent, and follow-up. By reducing manual tasks and streamlining data coordination, clinical teams benefit from improved workflow efficiency and better patient communication. Enhanced electronic health record connectivity ensures patients experience smoother journeys and greater access to personalized care. (Link)
- Emergence, backed by The Pritzker Organization, acquires MedEvolve, to Transform AI-Driven Revenue Cycle Management for Healthcare Providers: MedEvolve will accelerate development of advanced automation and analytics tools to help healthcare organizations address operational inefficiencies and financial pressures. Its platform offers real-time insights for process improvement and margin recovery, supporting increased transparency, effective collections, and sustainable performance management in complex revenue cycle operations. (Link)
- Get Well and RhythmX AI Combine Under SymphonyAI Group, to Form GW RhythmX and Advance Precision Care AI for 150 Health Systems and 85 Million Patients: The combined entity delivers integrated engagement and precision care using AI-driven data insights, streamlining patient support and clinical workflow for providers. Its enterprise-scale approach offers tailored recommendations, improved outcomes, and operational efficiency, with demonstrated success in enhancing care quality, readmission rates, and patient satisfaction across diverse healthcare settings. (Link)
- Diversis Capital Unites Genesis Automation Healthcare, Kermit, and Meperia to Launch First End-to-End Clinical Supply Chain Platform and Highlight $1B in Global Annual Savings for 100+ Hospitals and Health Networks: The Genesis platform streamlines hospital and ambulatory center supply chains with unified digital management for inventory, charge capture, and contract pricing. Automated workflows and analytics improve data quality, reduce waste, and strengthen compliance, enabling clinicians to prioritize patient care while finance teams achieve greater transparency and control over spending. (Link)
- Vituity Integrates Focus Medical Imaging, Expands Physician-Led Model Into Diagnostic and Interventional Radiology for Hospitals and Health Systems Nationwide: The partnership enhances clinical services with a physician-led approach, empowering medical professionals in decision-making and governance. Expanded diagnostic and interventional radiology offerings, combined with innovative teleradiology, improve operational efficiency and patient care. Hospitals and imaging centers gain more coordinated, effective, and sustainable service delivery across the healthcare continuum. (Link)
- OneOncology and Cancer Specialists of North Florida (CSNF) Forge Partnership, via its financial sponsor TPG, to Elevate Community-Based Cancer Care and Expand Integrated Oncology Services Across North Florida: The collaboration improves oncology care for thousands of patients with access to advanced diagnostics, accelerated clinical research, and streamlined treatment delivery. Patients benefit from reduced wait times, comprehensive support, and integrated technology resources, while clinicians retain independence and expand expertise. The alliance promotes regional access to innovative therapies and superior care coordination. (Link)
- Hyve acquires Health Grown Advisory Network (HGAN), Strengthening Healthcare Innovation Partnerships and Behavioural Health Tech Integration: The integration provides ongoing support and tailored connections for digital health innovators and organizations, enhancing marketing, strategy, and system navigation. Expanded advisory resources deepen collaboration, foster scalable partnerships, and enable health industry leaders to engage beyond traditional event cycles, increasing opportunities for impactful innovation and consumer health benefits. (Link)
- The Lockwood Group acquires Research To Practice (RTP), via its financial sponsor Ares Management, expanding Global Oncology Education: The partnership enhances global oncology education by combining proven training formats with advanced consulting and communication expertise. Oncology professionals gain access to innovative, evidence-based resources reflecting current clinical advances. This collaboration delivers practical knowledge, supports professional growth, and helps clinicians make informed decisions to improve patient outcomes worldwide. (Link)
News Healthcare Deals, Investments & Update Week ending Nov 10th 2025
1. BillionToOne (NASD: BLLN) raises $273 Million in U.S. IPO Led by J.P. Morgan, Piper Sandler, Jefferies, and William Blair
The firm’s technology powers advanced prenatal and oncology diagnostics through its Unity and Northstar tests. Analysts view its IPO success as reflecting growing investor confidence in biotech innovation despite wider market uncertainty. The offering signals renewed momentum in healthcare listings, inspired by other major sector filings such as Medline’s. (Link)
2. Sonida Senior Living (NYSE: SNDA) and CNL Healthcare Properties announce $1.8 Billion Merger Creating the Nation’s Eighth Largest Senior Housing Owner
The merger focuses on expanding nationwide senior living operations with an emphasis on quality care and operational integrity. Both companies aim to strengthen their market position through shared values and strategic growth in key U.S. regions, while investors anticipate improved financial performance and stronger long-term value within the senior housing sector. (Link)
3. QOL Medical to acquire Evoke Pharma (NYSE: EVOK) in All-Cash Deal Worth $11 Per Share
The agreement merges complementary strengths in gastrointestinal innovation, expanding access to advanced treatments for diabetic gastroparesis. Both companies underscored the transaction’s strategic value in broadening therapeutic offerings and commercial reach. Supported by cash reserves, the acquisition awaits regulatory and shareholder approval, marking a step toward enhanced capabilities in GI-focused patient care. (Link)
4. Organon sells Jada System to Laborie Medical Technologies in $465 Million Deal
The transaction supports reorganization and debt reduction, positioning both companies for strategic growth. Laborie will expand its maternal health portfolio by incorporating the Jada device and its specialized workforce. Organon aims to redirect focus toward women’s health biopharma opportunities after recent leadership transitions, declining sales, and halted drug development initiatives. (Link)
5. Lifecare Home Health acquires Infinity Hospice Care, via its financial sponsor Zenyth Partners, expands Hospice Services Across Nevada and Arizona
The collaboration enhances post-acute care delivery through unified expertise in compassionate and high-acuity hospice services. Combining national infrastructure with community-based operations, both organizations aim to elevate patient experiences centered on dignity and care quality. Leadership underscores innovation and continuity as key drivers in expanding coordinated healthcare across multiple states. (Link)
6. Optain Health acquires EyePACS to Advance AI-Driven Retinal Screening and Oculomics Innovation
The collaboration enhances early disease detection through advanced AI imaging, expanding access to preventive care and population health programs. EyePACS’s nationwide network will integrate Optain’s automation and multilingual capabilities, improving clinical efficiency and diagnostic scalability while advancing oculomics research aimed at identifying systemic diseases through non-invasive retinal analysis. (Link)
7. JLL Partners combines Vascular Technology Incorporated and Parks Medical Electronics to Build Vascular and Robotics Device Platform
The merger unites advanced capabilities in vascular diagnostics and Doppler ultrasound technologies to enhance precision and clinical performance. By combining innovation with U.S.-based production, the partnership focuses on improving device reliability and expanding access to next-generation vascular tools that support surgical, therapeutic, and diagnostic applications worldwide. (Link)
8. Omega Systems acquires PEAKE Technology Partners, via its financial sponsor Revelstoke Capital Partners to strengthen Healthcare Managed IT and Cybersecurity Capabilities
The acquisition enhances healthcare IT services through advanced data security, compliance, and AI-driven clinical capabilities. By integrating expertise in electronic health records and HIPAA management, the partnership aims to boost operational performance and patient outcomes while expanding regional reach and reinforcing leadership in secure, technology-driven healthcare infrastructure nationwide. (Link)
9. Acumed acquires TECHFIT Digital Surgery Assets to Advance Patient-Tailored Craniomaxillofacial Solutions
The integration brings advanced digital planning and reconstruction capabilities to improve precision in surgical procedures across multiple specialties. By expanding personalized, data-driven care, the company aims to advance innovation in reconstructive and orthopaedic solutions. Leadership additions and global strategy alignment will support broader adoption of patient-tailored surgical technologies worldwide. (Link)
10. RadNet and DeepHealth acquire Alpha RT to Expand Remote MRI Scanning and AI Safety Capabilities
The integration enhances imaging efficiency through AI-powered monitoring, advanced training, and resource optimization to tackle technologist shortages. By combining intelligent staffing with remote imaging technology, the partnership strengthens scalability and nationwide support. It aligns with continued investments in AI-driven diagnostics, expanding capabilities across multiple medical imaging modalities and platforms. (Link)
News Healthcare Deals, Investments & Update Week ending Oct 27th 2025
1. Hologic (NASD: HOLX) to go private in $18.3 Billion acquisition by Blackstone and TPG, Minority Stakes for Abu Dhabi Investment Authority and GIC The transaction is designed to deliver compelling value to shareholders and highlights continued innovation in women’s health and AI-driven diagnostics. Hologic will maintain its brand and headquarters while operating privately. The agreement includes a 45-day “go-shop” period, and closing remains subject to regulatory and shareholder approvals, with completion anticipated in the first half of 2026. (Link)
2. Novartis (NYSE: NVS) to acquire Avidity Biosciences (NASD: RNA) for $12 Billion; SpinCo to Emerge as Independent Cardiology-Focused Company The deal, unanimously approved by both boards, will give Novartis global rights to innovative RNA-based neuromuscular therapies and boost its neuroscience pipeline with potential first-in-class candidates. Avidity shareholders will receive additional SpinCo stock or cash linked to its cardiology assets. Regulatory and shareholder approvals are pending. (Link)
3. Eli Lilly (NYSE: LLY) to acquire Adverum Biotechnologies (NASD: ADVM) in Deal Centered on Ixo-vec Gene Therapy Lilly’s purchase will help advance Ixo-vec, a novel gene therapy for vision loss, offering shareholders potential milestone payments based on regulatory and sales goals. This late-stage treatment addresses a major unmet need for wet age-related macular degeneration. The acquisition also secures short-term funding for Adverum’s clinical progress. (Link)
4. Alkermes (NASD: ALKS) to acquire Avadel Pharmaceuticals (NASD: AVDL) for Up to $2.1 Billion, Expanding Sleep Medicine Portfolio with LUMRYZ™ Alkermes’ acquisition adds the FDA-approved LUMRYZ™, a once-at-bedtime sodium oxybate treatment for narcolepsy symptoms like cataplexy and excessive daytime sleepiness. The deal offers shareholders $18.50 upfront plus $1.50 contingent on FDA label expansion, a 38% premium over recent prices. Closing is expected in Q1 2026, enhancing Alkermes’ sleep medicine portfolio and leveraging Avadel’s expertise for future pipeline development. (Link)
5. DocGo (NASD: DCGO) acquires SteadyMD to Expand Telehealth Services Nationwide; SteadyMD Co-Founders Join Leadership Team DocGo acquired SteadyMD to expand its telehealth reach across all 50 states, integrating SteadyMD’s virtual clinician network with its mobile healthcare services. SteadyMD, expected to generate $25 million in 2025, serves over 3 million patients, including Fortune 10 clients. SteadyMD’s leadership joins DocGo’s team, and the acquisition is funded by DocGo’s cash reserves. (Link)
6. Lemonaid Health acquired by Bambu Ventures to relaunch as Independent Telemedicine Platform after Bankruptcy Lemonaid Health, after bankruptcy will pursue aggressive growth as an independent telemedicine and pharmacy platform. Bambu and Innova Partners provide executive leadership, focusing on affordable care, same-day prescriptions, and market expansion. Key board appointments and new investors support innovation and differentiation. (Link)
7. Opyn Health, Inc. acquires Empara to Integrate AI-Driven Benefits Engagement and Boost Platform for Self-Insured Healthcare Combining Opyn’s price transparency and virtual care expertise with Empara’s AI-powered app streamlines benefits administration and cost management for members and administrators. Empara’s founders join Opyn, and the unified platform will serve TPAs, brokers, and self-insured employers—aiming to replace legacy systems with a seamless digital access point for healthcare. (Link)
8. Oasis Health Partners® acquires PreferCare to Strengthen Value-Based, Preventive Primary Care for Seniors in North Carolina PreferCare enhances Oasis’s capabilities with in-home and virtual care for seniors, leveraging new tools, analytics, and clinical support. The partnership improves coordinated care, preventive screenings, and early interventions. By empowering physicians and supporting practices, Oasis advances health equity and outcomes, building healthier communities through a value-based care model. (Link)
9. Duly Health and Care acquire Woodridge Clinic, via its financial sponsors Ares Private Equity Group, Guidon Partners and Athyrium Capital Management, expanding Physician-led Primary Care Services across Chicagoland Woodridge Clinic, founded in 1986, excels in primary care, diabetes management, and occupational therapy. Joining Duly gives its team access to new resources and technology, expanding specialty care and services in Lemont, Lombard, and Woodridge. This partnership strengthens coordinated, patient-focused care for local families and supports ongoing provider recruitment. (Link)
10. Frontline Healthcare Partners acquires Integracare Inc. to drive expansion of Private-Pay Home Care across Ontario, Canada Integracare will benefit from expanded operational resources and Frontline’s healthcare investment expertise to reach new communities. The partnership preserves its focus on personalized, quality home care and workplace excellence, supporting growth beyond Toronto, Mississauga, and Ottawa. This move helps advance Integracare’s mission and expands personalized home health solutions across Ontario. (Link)
11. Cerebral raises $25 Million in Latest Funding Round, Accelerating Growth and Platform Integration The capital infusion, following the Resilience Lab acquisition, will support Cerebral’s nationwide expansion, platform integration, and quality initiatives like improved clinical training. Funds will enhance telehealth services, solidify insurance partnerships, and drive innovation in therapy, psychiatry, and medication management, as the company rebuilds after leadership and regulatory challenges. (Link)
12. Counsel Health raises $25 Million Series A Led by Andreessen Horowitz and GV to Launch Physician-Supervised AI Front Door for Healthcare Following $11 Million Seed Round Counsel Health’s platform delivers instant, context-aware medical guidance via chat or voice, using AI with physician oversight for diagnosis, prescriptions, or referrals and unlimited follow-up. It reports a 96% resolution rate, rapid response times, and measurable cost savings. Serving 100,000+ members now, it’s expanding to reach millions nationwide. (Link)
13. Faeth Therapeutics raises $25 Million, led by S2G Investments, with Support from KdT Ventures, Khosla Ventures, Future Ventures, Cantos Ventures, Digitalis Ventures, B Capital Group, Avicella Capital, THO Seed Fund and Others Faeth Therapeutics’ funding will support a randomized phase 2 trial of its PIKTOR regimen after an 80% response rate and 11-month median progression-free survival in endometrial cancer. The capital enables insulin control research, expansion into rectal cancer and rare metabolic disorders, and growth of the MetabOS™ precision oncology platform. (Link)